



Immuneering to Present at the Morgan Stanley Healthcare Conference

September 6, 2023

CAMBRIDGE, Mass., September 6, 2023 -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Harold "E.B." Brakewood, Chief Business Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Fireside Chat and 1x1 Investor Meetings

Presentation: September 13, 2023 from 10:10 - 10:50 am ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering's website at [Events & Presentations | Immuneering Corporation](#).

About Immuneering Corporation

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering's lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company's development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:

Gina Nugent
Nugent Communications
617-460-3579
gina@nugentcommunications.com

Investor Contacts:

Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com

or

Kiki Patel, PharmD
Gilmartin Group
332-895-3225
kiki@gilmartinir.com